Healthcare shares were flat in pre-market trade Thursday.
Celgene Corporation ( CELG ) nudged up in pre-market trade after saying its Q4 earnings rose 14% to $1.51 per share although missing the average $1.55 Capital IQ analyst estimate. Sales were higher at $1.76 million from $1.45 million a year earlier compared to the $1.7 billion consensus estimate.
And, Eli Lilly ( LLY ) reported Q4 non-GAAP EPS of $0.74, in line with the analyst consensus on Capital IQ. Revenue was $5.80 bln, better than expectations of $5.46 bln.
For 2014, the company confirmed its guidance of $2.77 to $2.85 per share, vs. Street estimates of $2.81 per share.
Finally, Quest Diagnostics ( DGX ) reported better-than-expected financial results for Q4, or the quarter ended Dec. 31, 2013, and provided FY14 earnings guidance that fell short of the Street consensus.
DGX reported Q4 reported adjusted EPS of $1.03. Analysts polled by Capital IQ were expecting EPS of $0.93.
Revenues were $1.76 billion, down 1% from $1.77 billion in the same quarter last year. Analysts were looking for revenues of $1.74 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.